Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
983 GBX | +0.51% | +0.82% | -41.59% |
May. 03 | Jefferies cuts AJ Bell; Deutsche likes ConvaTec | AN |
May. 01 | EXECUTIVE CHANGES: New chairs for CVS Group, LSL Property and Videndum | AN |
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-41.59% | 882M | B | ||
-32.02% | 133M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CVSG Stock
- Ratings CVS Group plc